Analyzing body fluids in narcolepsy patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on the proteomics and metabolomics of body fluids in patients with narcolepsy, comparing them to healthy volunteers. It aims to identify potential molecular markers associated with narcolepsy by analyzing blood, urine, stool, and cerebrospinal fluid samples. The study will assess various factors, including sleepiness and sleep quality, using established scales. By understanding the biochemical differences, the research seeks to shed light on the pathogenesis of narcolepsy and improve diagnostic accuracy.

Why it matters

Who can join: the full rules

Inclusion Criteria

* All patients met the diagnostic criteria of the International Classification of Sleep Disorders, Third edition (ICSD-3).

Exclusion Criteria

* primary hypersomnia or hypersomnia due to shift work, sleep deprivation and other sleep rhythm disturbances;
* excessive sleep due to drug abuse;
* suffering from Parkinson's disease, Alzheimer's disease and other nervous system diseases and mental diseases;
* complicated with heart, lung, liver, kidney, blood endocrine system and other basic diseases, or acute chronic infection in a short period of time;
* Use of sedatives, hypnotics, antidepressants, lithium and dopamine receptor antagonists for two weeks before examination;
* patients who cannot cooperate with PSG and MSLT due to various factors.

Where it's running

• Qilu Hospital of Shandong University
  Jinan, Shandong, China Recruiting

Study contacts

• Study coordinator: haiyun li
• Email: haiyunli1122@163.com
• Phone: 18560088921

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HBS-301 for Narcolepsy: daily wakefulness and sleepiness improvement in adults

  This Phase 3 study tests HBS-301 vs placebo in adults with narcolepsy to see if it helps with daytime sleepiness, cataplexy, sleepiness, and fatigue.

  Recruiting at 29 sites Phase 3 Harmony Biosciences Management, Inc. · Birmingham, Alabama and 52 other locations · NCT07675135

• Expanded-dosing Xywav vs placebo in narcolepsy and IH

  This study tests whether expanded nightly dosing of Xywav helps adults with narcolepsy or idiopathic hypersomnia, compared with placebo.

  Recruiting at 15 sites Phase 3 Jazz Pharmaceuticals · Birmingham, Alabama and 14 other locations · NCT07625280

• Testing Lu AH69593 for safety and tolerance in healthy adults and people with narcolepsy

  This study tests whether Lu AH69593 is safe and well tolerated in adults, including those with narcolepsy, and looks at how the body processes the drug with and without food.

  Recruiting Phase 1 H. Lundbeck A/S · Helsinki and 1 other locations · NCT07613710

• Samelisant for Narcolepsy: A Phase 3 Test for EDS and Cataplexy

  This phase 3 study tests whether Samelisant can reduce daytime sleepiness and cataplexy in adults with narcolepsy.

  Recruiting Phase 3 Suven Life Sciences Limited · Columbia, South Carolina · NCT07540364

• E2086 for adults with narcolepsy: find the best dose compared with placebo

  This study tests different doses of E2086 against placebo in adults with narcolepsy to see if it reduces daytime sleepiness.

  Recruiting at 2 sites Phase 2 Eisai Inc. · Santa Ana, California and 56 other locations · NCT07493265

• Exploring the effects of light and electrical stimulation on sleep disorders

  This study is testing if light therapy and brain stimulation can help people with sleep disorders like insomnia and narcolepsy get better sleep.

  Recruiting Second Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT06797284

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.